Table 2.
Subgroup analysis at baseline, after HomeChoice Claria machine and after connection with remote patient monitoring (RPM) system.
| Clinical and laboratory parameters | Good adherence group (n=40) | P value between groups in phase 1 | |||
|---|---|---|---|---|---|
| Phase 1: HomeChoice, baseline | Phase 2: HomeChoice Claria without RPM | Phase 3: HomeChoice Claria with RPM | P value | ||
| Age (years) | 53.2±12.7 | – | – | – | 0.064 |
| Weight (Kg) | 56.5 (49.1–67) | 0.101 | |||
| Male, n (%) | 20 (50) | 0.003* | |||
| DM | 12 (30) | 0.437 | |||
| Hypertension | 36 (90) | 0.14 | |||
| PD vintage | 68.6±35.8 | 0.813 | |||
| Non-adherence rate (%) | 0 | 2.6±10.4a | 2.8±11.3a | 0.001* | <0.0001* |
| BUN (mg/dL) | 57.5±12.2 | 62.8±13.9a | 63.7±13.6a | 0.006* | 0.053 |
| Serum creatinine (mg/dL) | 12.8±3.5 | 13.2±3.8 | 13.1±3.7 | 0.086 | 0.654 |
| Sodium (meq/L) | 137 (136–140.8) | 138 (135–140) | 138 (135–140.8) | 0.395 | 0.563 |
| Potassium (meq/L) | 3.99±0.68 | 4.01±0.54 | 3.68±0.73a,b | 0.005* | 0.545 |
| CRP (mg/dL) | 2.82 (0.47–10.94) | 2.81 (0.45–7.66) | 2 (0.63–4.84) | 0.086 | 0.044* |
| Residual urine volume (mL) | 153±372 | 101±244 | 87±224 | 0.053 | 0.152 |
| Residual CCR (mL/min/1.73 m2) | 0 (0–0.269) | 0 (0–0.134)a | 0 (0–0.131)a | 0.002* | 0.36 |
| Total Kt/V per week | 62.05 (1.84–2.21) | 2 (1.83–2.21) | 2.02 (1.79–2.29) | 0.664 | 0.551 |
| PD Kt/V per week | 1.98±0.25 | 1.96±0.27 | 1.99±0.26 | 0.461 | 0.317 |
| Clinical and laboratory parameters | Poor Adherence Group (n=11) | P value between groups in phase 1 | |||
| Phase 1: HomeChoice, baseline | Phase 2: HomeChoice Claria without RPM | Phase 3: HomeChoice Claria with RPM | P value | ||
| Age (years) | 45.3±10.5 | 0.064 | |||
| Weight (Kg) | 71 (54.1–75.8) | 0.101 | |||
| Male, n (%) | 11 (100) | 0.003* | |||
| DM | 9 (81.8) | 0.437 | |||
| Hypertension | 8 (72.7) | 0.14 | |||
| PD vintage | 72.7±52.3 | 0.813 | |||
| Non-adherence rate (%) | 48.4±36.9 | 14.2±16.3a | 12.4±17.3a | 0.007* | <0.0001* |
| BUN (mg/dL) | 66.3±15.9 | 66.2±13.4 | 71.4±11.6 | 0.268 | 0.053 |
| Serum creatinine (mg/dL) | 13.3±2.0 | 13.6±2.3 | 14.4±2.5a,b | 0.017* | 0.654 |
| Sodium (meq/L) | 136 (136–140) | 139 (136–141) | 139 (137–141) | 0.061 | 0.563 |
| Potassium (meq/L) | 4.13±0.71 | 4.09±0.62 | 3.46±0.69a,b | 0.002* | 0.545 |
| CRP (mg/dL) | 6.71 (2.22–24.52) | 2.96 (0.98–9.52) | 7.59 (1.53–13.86) | 0.148 | 0.044* |
| Residual urine volume (mL) | 532±794 | 473±707 | 407±602 | 0.136 | 0.152 |
| Residual CCR (mL/min/1.73 m2) | 0 (0–4.093) | 0 (0–3.507) | 0 (0–2.289) | 0.039* | 0.36 |
| Total Kt/V per week | 1.89 (1.79–2.27) | 1.84 (1.71–2.03) | 1.81 (1.75–2) | 0.035* | 0.551 |
| PD Kt/V per week | 1.79±0.52 | 1.69±0.35 | 1.79±0.38 | 0.26 | 0.317 |
Normally distributed continuous variables are presented as the mean±standard deviation (paired, repeated-measure one-way ANOVA test; between group, independent t test); variables not normally distributed are presented as the median and interquartile range (paired, Friedman test; between-group, Mann-Whitney U test); categoric variables are presented as number (%) and analyzed by chi-squared test.
Values of P<0.05, were considered statistically significant;
P<0.05, compared to phase 1;
P<0.05, compared to phase 2.
DM – diabetes mellitus; PD – peritoneal dialysis; BUN – blood urea nitrogen; CRP – C-reactive protein; CCR – creatinine clearance rate.